Risk of cytopenia and infection with early intervention for CRS after CAR T-cell therapy in LBCL
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2025-12-07
Просмотров: 59
Описание:
Gloria Iacoboni, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses a retrospective analysis evaluating the management of cytokine release syndrome (CRS) after CAR T-cell therapy for large B-cell lymphoma (LBCL), highlighting that early intervention for CRS at grade 1 was found to be associated with an increased risk of cytopenias and infections but did not affect the incidence of immune effector cell-associated neurotoxicity syndrome (ICANS). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
![AI in Healthcare: Why There’s No Such Thing as an “AI Strategy” | Todd Mersch [Inovalon INOvators]](https://imager.clipsaver.ru/1US8nR4st8c/max.jpg)
